Synonyms: HAVcr-2, CD366
Cobolimab (Anti-TIM-3 / HAVCR2 / CD366) is a monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145 KD.
Shimon Sakaguchi
Nature Communications 2025,16, Article number:1325
David Baker
Dev Cell 2023, 58(20):2163-2180.e9.
David Julius
Cell 2017, 185-198.e16
Michael Houghton
Cell Chem Biol, 2020, 27(7):780-792.e5
Charles M. Rice
Cell 2018, 172(3):423-438.e25
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Cobolimab (Anti-TIM-3 / HAVCR2 / CD366) is a monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145 KD.
|
References |
|---|
| CAS No. | 2022215-65-0 |
|---|---|
| Molecular Weight | 145 |
| Isotype | Human IgG4SP |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT02817633 | ACTIVE_NOT_RECRUITING | Drug: TSR-022|Drug: Nivolumab|Drug: TSR-042|Drug: TSR-033|Dr | Neoplasms | Tesaro, Inc. | 2016-07-08 | PHASE1 |
| NCT06056895 | ACTIVE_NOT_RECRUITING | Drug: Tuparstobart|Drug: Verzistobart | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Merkel Cell Carcinoma AJCC v8; Merkel Cell Carcinoma | University of Washington | 2023-11-08 | PHASE2 |
| NCT06608940 | WITHDRAWN | Drug: BC3402|Drug: Durvalumab|Drug: Tremelimumab | Hepato Cellular Carcinoma (HCC) | Case Comprehensive Cancer Center | 2025-11 | PHASE1; PHASE2 |
| NCT04446351 | ACTIVE_NOT_RECRUITING | Drug: GSK6097608|Drug: Dostarlimab|Drug: Cobolimab|Drug: Bel | Neoplasms | GlaxoSmithKline | 2020-06-25 | PHASE1 |
| NCT05357651 | RECRUITING | Drug: LB1410 | Solid Tumor; Lymphoma | L & L Bio Co., Ltd., Ningbo, China | 2022-08-12 | PHASE1 |
| NCT06238635 | ACTIVE_NOT_RECRUITING | Drug: Dostarlimab|Drug: Cobolimab | Cervical Cancer; Advanced Cervical Carcinoma; Metastatic Cervical Cancer; Metastatic Cervical Carcinoma; Recurrent Cervical Carcinoma | Meghan Shea | 2024-03-11 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2025-10-28)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.